24 results about "Hormone dependence" patented technology

This invention discloses a strain of Bifidobacterium animalis subspecies TRT-2A with allergy-relieving effects and its extracellular vesicle applications. The strain TRT-2A is deposited at the China Center for Type Culture Collection (CCTCC) on November 21, 2025, with accession number CCTCC NO:M 20252645. This strain is highly acid-resistant and exhibits good tolerance to artificial gastric and intestinal fluids. It effectively inhibits bacteria, particularly Streptococcus pyogenes, Streptococcus agalactiae, and / or Escherichia coli. Experimental results show that this strain can alleviate hormone-dependent dermatitis and effectively improve dermatitis symptoms such as erythema and desquamation. Furthermore, extracellular vesicles prepared using TRT-2A can effectively improve skin elasticity and reduce wrinkles. Therefore, the Bifidobacterium animalis subspecies TRT-2A of this invention has multiple functions and is worthy of further promotion and application.

This invention discloses the application of platelet-reactive protein-4 (THBS4) in the diagnosis and treatment of endometriosis. Through bioinformatics integration analysis, clinical sample validation, and in vitro and in vivo experiments, this invention confirms that THBS4 is significantly highly expressed in both ectopic lesions and peripheral blood of patients with endometriosis, and its expression level is positively correlated with disease severity. The area under the receiver operating characteristic (AUC) curve for THBS4 alone in diagnosing endometriosis is 0.930, significantly superior to cancer antigen 125 (CA125); the AUC for the combined diagnosis of THBS4 and CA125 reaches 0.968. Simultaneously, silencing the THBS4 gene effectively inhibits the proliferation, migration, and invasion of human endometrial stromal cells, and significantly reduces the volume and fibrosis area of ​​ectopic lesions in a mouse model of endometriosis. This invention provides a highly sensitive and specific new biomarker for the non-invasive or minimally invasive early diagnosis of endometriosis, and provides new targets and candidate drugs for non-hormone-dependent targeted therapy.

The current invention is in the field of molecular biology / pharmacology and provides novel 3-oxabicyclo[3.3.1]nonene compounds and derivatives that modulate the effects of the classical estrogen receptors alpha and beta (ERalpha and ERbeta) with little to no biological or physiological effects on the G protein-coupled estrogen receptor GPER (also known as GPR30). These compounds may function as agonists and / or antagonists of one or more of the disclosed classical estrogen receptors. Diseases that are mediated through one or more of these receptors include cancer (including but not limited to breast (particularly endocrine or anti-hormone resistant, and for the prevention / reduction of endocrine or anti-hormone resistance), reproductive and other hormone-dependent cancers, leukemia, colon cancer, prostate cancer), reproductive (genito-urological) including endometritis, prostatitis, polycystic ovarian syndrome, bladder control, hormone-related disorders, hearing disorders, cardiovascular conditions including hot flashes and profuse sweating, hypertension, stroke, obesity, osteoporosis, hematologic diseases, vascular diseases or conditions such as venous thrombosis, atherosclerosis, among numerous others and disorders of the central and peripheral nervous system, including depression, insomnia, anxiety, multiple sclerosis, neuropathy, neurodegenerative disorders (such as Parkinson's disease and Alzheimer's disease), as well as inflammatory bowel disease, Crohn's disease, coeliac (celiac) disease and related disorders of the intestine, among numerous others as described herein. A contraceptive indication to prevent or reduce the likelihood of pregnancy after intercourse is a further aspect of the present invention.

The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and / or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.

Disclosed are a compound shown in formula I and racemate, stereoisomer, tautomer, isotopically labeled, nitroxide, solvate, polymorph, metabolite, ester, prodrug or pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same, a preparation method thereof, and a use thereof as a GHSR agonist in the preparation of a drug for the diagnosis, prevention and / or treatment of growth hormone-dependent diseases, the structure of formula I is as follows:

The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and / or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.

The present invention aims to provide a method for producing 3-methyl-1,2,4-thiadiazole-5-carbohydrazide safely and in high yield. The present invention relates to a method for producing 3-methyl-1,2,4-thiadiazole-5-carbohydrazide or a salt thereof, via a compound represented by the formula (2):wherein R is a C1-4 alkyl group, which is a novel compound, or a salt thereof. According to the present invention, a safe and high-yielding production method of 3-methyl-1,2,4-thiadiazole-5-carbohydrazide, which is an important synthetic intermediate for fezolinetant useful as a medicament for the treatment of sex hormone-dependent diseases, can be provided.

The application belongs to the technical field of biological medicine, and particularly relates to application of CDC37 protein in preparation of Treg cell dysregulation disease treatment product. The application obtains a CDC37 protein with immunoregulatory function and high expression through mass spectrum analysis and bioinformatics analysis on proteins of lung stage child worms of Japanese blood flukes. The amino acid sequence of the CDC37 protein is shown as SEQ ID NO. 1, and the nucleotide sequence of the gene coding the CDC37 protein is shown as SEQ ID NO. 2. Experimental results show that the CDC37 protein can realize the effect of non-hormone-dependent long-acting relief of Treg cell dysregulation diseases by inducing Treg cell expansion, inhibiting Th2 response and reducing airway hyperresponsiveness, and can be used for preparation of Treg cell dysregulation disease treatment product.

The invention discloses rhizoma bletillae spot-fading powder and a preparation method thereof, and belongs to the technical field of traditional Chinese medicine, and the rhizoma bletillae spot-fading powder comprises the following raw materials in parts by weight: 10-30 parts of rhizoma bletillae, 10-30 parts of radix astragali, 10-30 parts of radix notoginseng, 10-30 parts of lily, 10-30 parts of rose, 10-30 parts of radix paeoniae alba, 10-30 parts of radix angelicae, 10-30 parts of pearl powder, 10-30 parts of coix seed and 10-30 parts of liquorice. The traditional Chinese medicine composition can repair the skin barrier function, enhance the skin resistance, reduce external stimulation, relieve sensitive redness, regulate water-oil balance, improve the problems of much oil and coarse pores and maintain the healthy and stable state of the skin, is prepared from pure traditional Chinese medicines, is mild in conditioning, does not have any toxic or side effect after being used for a long time, and has a repairing effect on hormone-dependent skin.

The invention relates to the use of a pharmaceutical medication comprising an aromatase inhibitor, preferably a steroidal aromatase inactivator and an antioxidant as effective ingredients for the treatment of sex hormone-dependent diseases. Furthermore, the invention relates to a composition comprising an aromatase inhibitor / —inactivator and α-lipoic acid and / or extract of green tea containing polyphenols. The combination of an aromatase inhibitor and—inactivator and α-lipoic acid and / or extract of green tea containing polyphenols is particularly suitable for the treatment of sex hormone-dependent diseases as well as for the treatment of benign tumors such as e.g. lipomatoses as occurring in Madelung's disease.

The present disclosure provides industrially scalable methods of making (Z)-endoxifen or a salt thereof, crystalline forms of endoxifin, and compositions comprising them. The present disclosure also provides methods for treating hormone-dependent breast and hormone-dependent reproductive tract disorders.

The invention discloses an application of cooperation of a chairsi acupoint and acupuncture in facial paralysis catgut embedding intervention, relates to the technical field of traditional Chinese medicine acupuncture treatment, and aims at solving the problems that in existing facial paralysis treatment, the acupuncture stimulation time is short, catgut embedding is mostly suitable for the late stage, hormone dependence is caused, and the sequelae risk is high. According to the application, early-stage facial paralysis patients are screened, facial local acupoint acupuncture is firstly carried out to quickly relieve symptoms, then far-end acupoints of the board Qi acupoints are selected, medical catgut is adopted for acupoint catgut embedding, and the synergistic effect of short-term acupuncture intervention and long-acting catgut embedding stimulation is achieved. Clinical tests prove that the synergistic application can significantly prolong the acupoint stimulation duration, regulate channel qi, stimulate healthy qi, effectively improve the facial nerve function and body and social life functions (facial disability index score) of a patient, shorten the treatment course, reduce the hormone use amount and use time, and reduce the occurrence probability of intractable facial paralysis. The catgut is free of toxic and side effects, convenient to operate and high in patient compliance, a novel traditional Chinese medicine suitable technology is provided for early intervention of facial paralysis, social and economic benefits are remarkable, and the catgut is suitable for clinical popularization.

The invention relates to a composition for improving vaginal dryness and relaxation and a preparation method thereof, the composition comprises a fusion protein as shown in SEQ ID NO: 4, the fusion protein RGD-Collagen-FGF2 is formed by connecting an RGD element (SEQ ID NO: 1), a human III-type collagen active fragment (SEQ ID NO: 2) and an FGF2 active fragment (SEQ ID NO: 3) through a linker to form a'retention-repair-regeneration 'synergistic network effect: RGD realizes positioning retention, Collagen constructs an ECM (extracellular matrix) scaffold, and the fusion protein is used for improving vaginal dryness and relaxation. The FGF2 activates epithelial regeneration; in a vaginal dry mouse model, local administration of the fusion protein can significantly improve vaginal epithelial thickness, ECM water content and mucoprotein expression and reduce epithelial permeability, the effect is better than that of estriol positive drugs, mucosal atrophy is reversed from a pathological mechanism for the first time, and hormone dependence risks are avoided.

To provide a dosage regimen for safely and effectively treating androgen-dependent prostate cancer without causing testosterone surge and / or other side effects of GnRH agonist therapy such as urinary tract infection or joint pain-related or cardiovascular side effects.SOLUTION: A relatively low dose of degarelix GnRH antagonist is provided about once every 28 days (e.g. once a month).SELECTED DRAWING: Figure 2

The purpose of the present invention is to provide a composition having an inhibitory action on the proliferation of hormone-dependent cells in order to make effective use of and add value to pomegranate seeds to be discarded.　A pharmaceutical composition for inhibiting the proliferation of hormone-dependent cells according to the present invention is characterized by containing pomegranate seed extract. A preferred embodiment of the pharmaceutical composition for inhibiting the proliferation of hormone-dependent cells according to the present invention is characterized in that the hormone-dependent cells are prostate cells. A preferred embodiment of the pharmaceutical composition for inhibiting the proliferation of hormone-dependent cells according to the present invention is characterized in that the prostate cells are androgen-dependent or independent cells.

The invention provides a cortex phellodendri composition for treating facial hormone-dependent dermatitis and a preparation method of the cortex phellodendri composition, and relates to the technical field of traditional Chinese medicines. The golden cypress composition is prepared from the following traditional Chinese medicines in parts by weight: 5-15 parts of golden cypress, 3-10 parts of fructus forsythiae, 2-7 parts of honeysuckle, 2-7 parts of oriental wormwood, 1-4 parts of dandelion and 0.5-2 parts of cassia twig. The cortex phellodendri composition disclosed by the invention can be used for treating hormone-dependent dermatitis after being coated or pasted on the face, and is quick in effect taking, good in effect and not easy to relapse.

The invention belongs to the technical field of biological medicine, and particularly relates to application of CDC37 protein in preparation of a product for treating Treg cell dysfunctional diseases, the CDC37 protein with an immune regulation function and high expression is obtained by performing mass spectrometry and biosignal analysis on protein of schistosoma japonicum lung-stage juvenile worms, the amino acid sequence of the CDC37 protein is shown as SEQ ID NO.1, and the CDC37 protein can be applied to preparation of a product for treating Treg cell dysfunctional diseases. The nucleotide sequence of the gene for coding the CDC37 protein is as shown in SEQ ID NO. 2. Experimental results show that CDC37 protein can achieve the effect of non-hormone-dependent long-acting alleviation of the Treg cell dysregulated diseases by inducing Treg cell amplification, inhibiting Th2 reaction and reducing airway hyperreactivity, and can be used for preparing a product for treating the Treg cell dysregulated diseases.

Compounds of Formula (I), pharmaceutical compositions or kits thereof are disclosed. Wherein A1 is C (O) or CHRz1, Rz1 is OH, amino, imino, halogen, (C1-C5) alkoxy, OC (O) (C1-C5) alkyl, and OSO2-amino; a2 is CH2 or O; r1 is hydrogen, a (C1-C5) alkyl group optionally substituted by one or more Z substituents, a (C1-C5) alkoxy group optionally substituted by one or more Z substituents, a (C2-C5) alkenyl group optionally substituted by one or more Z substituents, a (C2-C5) alkynyl group optionally substituted by one or more Z substituents; (C3-C8) cycloalkyl, aryl or heteroaryl groups; z is halogen, OH, (C1 to C5) alkyl, (C1 to C5) haloalkyl, (C1 to C5) alkoxy, (C1 to C5) haloalkoxy, or amino; r2 is a heterocyclic aromatic ring having 5, 6 or 7 members and having at least one N, S and / or O; r3 is a (C1-C5) alkyl group, which is substituted by one or more Br, Br76; i, I123, I124 or I131 substitutions; m is an integer selected from 0 to 2; n is an integer selected from 0 to 2; and p is an integer selected from 0 to 5. The compounds of formula I are inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for use in the treatment or prevention of steroid hormone dependent diseases such as breast cancer, lung cancer, prostate cancer, ovarian cancer, uterine cancer, endometrial cancer and endometrial hyperplasia. (I).

The invention discloses a night dressing containing a cortex phellodendri composition as well as a preparation method and application of the night dressing, and relates to the technical field of traditional Chinese medicines. The night dressing comprises raw material medicines and an auxiliary agent, and the raw material medicines comprise the following components in parts by weight: 30-50 parts of a cortex phellodendri residue extract, 30-50 parts of radix sophorae flavescentis, 45-90 parts of honeysuckle, 30-50 parts of radix scutellariae, 45-60 parts of angelica sinensis and 40-60 parts of radix polygonati officinalis; the auxiliary materials comprise 10-15 parts of sodium hyaluronate and 40-60 parts of glycerol. The night dressing containing the cortex phellodendri composition can resist inflammation and inhibit bacteria, block inflammatory vicious circle, accelerate skin barrier repair and treat facial hormone-dependent dermatitis.

The invention relates to the technical field of plant tissue culture and asexual propagation, and particularly discloses a tuber section propagation method for nephrolepis auriculata, which comprises the steps of endophyte selective enrichment culture, section preparation, synergistic induction culture, acclimatization and transplantation and the like. Wherein the formula composition of the rooting and germination culture medium is associated with the carbon source selection of the endophyte growth-promoting culture medium; according to the method, a staged plant-microorganism collaborative culture system based on carbon source adaptation is established, so that the biological function of tuber endophyte flora is effectively utilized, and the breeding efficiency and the seedling quality are remarkably improved; according to the method, the biological stability of a culture system is enhanced while the exogenous hormone dependence is reduced, an innovative and efficient solution is provided for solving the problems of high pollution rate, insufficient seedling robustness, large transplanting survival rate fluctuation and the like in traditional tuber propagation, and the method is suitable for large-scale and standardized production.

This invention relates to new use of dual NK-1 / NK-3 receptor antagonists or a pharmaceutically acceptable salt thereof in the treatment of sex-hormone dependent diseases.

The present invention aims to provide a method for producing 3-methyl-1, 2, 4-thiadiazole-5-carbohydrazide safely and in high yield. The present invention relates to a method for producing 3-methyl-1,2,4-thiadiazole-5-carboxamide or a salt thereof without using toxic carbon monoxide gas. According to the present invention, a safe and high-yielding production method of 3-methyl-1, 2, 4-thiadiazole-5-carbohydrazide, which is an important synthetic intermediate 21 for fezolinetant useful as a medicament for the treatment of sex hormone-dependent diseases, can be provided.

This invention discloses the application of Altai Mountain natural low-deuterium water in skin barrier repair and non-therapeutic skin soothing care, belonging to the field of skincare technology. The Altai Mountain natural low-deuterium water originates from the pristine glacial water source of the central Altai Mountains (the source of the Kuran River basin), with specific physicochemical indicators. After sterilization, it can be used directly as a stock solution or in combination, applicable to various scenarios of non-therapeutic care, including sensitive skin, post-cosmetic procedures, post-sun exposure, and post-operative care for mild hormone-dependent dermatitis. This invention leverages the low-deuterium properties and synergistic effects of natural minerals to solve the problems of strong irritation and simple mechanisms in existing products. A search reveals no conflict with existing patents, demonstrating outstanding novelty, inventiveness, and practicality. It possesses high technical barriers, strong industrialization feasibility, and is suitable for the development of high-end skincare products.

The present application relates to a kind of gonadotropin releasing hormone antagonists, it has the antagonistic activity to gonadotropin releasing hormone, and can be used to prevent or treat sex hormone-dependent diseases, such as benign prostatic hypertrophy, uterine fibroids, endometriosis, uterine fibroids, precocious puberty, amenorrhea, premenstrual syndrome, dysmenorrhea and the like, or its prodrug, or its pharmaceutically acceptable salt, or its hydrate or solvate, and the pharmaceutical composition containing it.